Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 14, 2012

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2019

Conditions
Recurrent Malignant Solid NeoplasmRecurrent MelanomaRecurrent Primary Central Nervous System NeoplasmRecurrent Thyroid Gland CarcinomaRefractory Malignant Solid NeoplasmRefractory Primary Central Nervous System NeoplasmThyroid Gland Medullary Carcinoma
Interventions
DRUG

Cabozantinib S-malate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (23)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

Children's Oncology Group, Philadelphia

20010

Children's National Medical Center, Washington D.C.

20892

National Institutes of Health Clinical Center, Bethesda

30322

Children's Healthcare of Atlanta - Egleston, Atlanta

35233

Children's Hospital of Alabama, Birmingham

38105

Saint Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children, Indianapolis

48109

C S Mott Children's Hospital, Ann Arbor

53226

Children's Hospital of Wisconsin, Milwaukee

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

60611

Lurie Children's Hospital-Chicago, Chicago

63110

Washington University School of Medicine, St Louis

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

92868

Children's Hospital of Orange County, Orange

94143

UCSF Medical Center-Parnassus, San Francisco

94158

UCSF Medical Center-Mission Bay, San Francisco

97239

Oregon Health and Science University, Portland

98105

Seattle Children's Hospital, Seattle

M5G 1X8

Hospital for Sick Children, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01709435 - Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors | Biotech Hunter | Biotech Hunter